CN104203267A - 用于治疗流感和副流感患者的方法、化合物和组合物 - Google Patents

用于治疗流感和副流感患者的方法、化合物和组合物 Download PDF

Info

Publication number
CN104203267A
CN104203267A CN201380009763.6A CN201380009763A CN104203267A CN 104203267 A CN104203267 A CN 104203267A CN 201380009763 A CN201380009763 A CN 201380009763A CN 104203267 A CN104203267 A CN 104203267A
Authority
CN
China
Prior art keywords
patient
das181
virus
infection
sialidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380009763.6A
Other languages
English (en)
Chinese (zh)
Inventor
朗·莫斯
李铁军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ansun Biopharma Inc
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Priority to CN201811368987.7A priority Critical patent/CN109529026A/zh
Publication of CN104203267A publication Critical patent/CN104203267A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201380009763.6A 2012-02-17 2013-02-19 用于治疗流感和副流感患者的方法、化合物和组合物 Pending CN104203267A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811368987.7A CN109529026A (zh) 2012-02-17 2013-02-19 用于治疗流感和副流感患者的方法、化合物和组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261600545P 2012-02-17 2012-02-17
US61/600,545 2012-02-17
US201261727627P 2012-11-16 2012-11-16
US61/727,627 2012-11-16
PCT/US2013/026754 WO2013123521A1 (en) 2012-02-17 2013-02-19 Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811368987.7A Division CN109529026A (zh) 2012-02-17 2013-02-19 用于治疗流感和副流感患者的方法、化合物和组合物

Publications (1)

Publication Number Publication Date
CN104203267A true CN104203267A (zh) 2014-12-10

Family

ID=48984833

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380009763.6A Pending CN104203267A (zh) 2012-02-17 2013-02-19 用于治疗流感和副流感患者的方法、化合物和组合物
CN201811368987.7A Pending CN109529026A (zh) 2012-02-17 2013-02-19 用于治疗流感和副流感患者的方法、化合物和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811368987.7A Pending CN109529026A (zh) 2012-02-17 2013-02-19 用于治疗流感和副流感患者的方法、化合物和组合物

Country Status (9)

Country Link
US (5) US20130280332A1 (cg-RX-API-DMAC7.html)
EP (1) EP2841092B1 (cg-RX-API-DMAC7.html)
JP (1) JP2015508780A (cg-RX-API-DMAC7.html)
CN (2) CN104203267A (cg-RX-API-DMAC7.html)
AU (3) AU2013221230A1 (cg-RX-API-DMAC7.html)
CA (1) CA2864746A1 (cg-RX-API-DMAC7.html)
ES (1) ES2970401T3 (cg-RX-API-DMAC7.html)
IL (2) IL234116B (cg-RX-API-DMAC7.html)
WO (1) WO2013123521A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
EP2571875A4 (en) 2010-05-14 2013-10-30 Dana Farber Cancer Inst Inc CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
US9975896B2 (en) 2013-07-25 2018-05-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
JP2017506666A (ja) 2014-02-28 2017-03-09 テンシャ セラピューティクス，インコーポレイテッド 高インスリン血症に関連した症状の処置
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
CN106793775B (zh) 2014-08-08 2020-06-02 达纳-法伯癌症研究所股份有限公司 二氢碟啶酮衍生物及其用途
KR20170068597A (ko) 2014-10-27 2017-06-19 텐샤 세러퓨틱스 인코포레이티드 브로모도메인 저해제
US20190000860A1 (en) * 2014-11-06 2019-01-03 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
WO2016073956A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
WO2016200916A1 (en) * 2015-06-08 2016-12-15 Ansun Biopharma, Inc. Treatment of human metapneumovirus
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
EP3347021A4 (en) 2015-09-11 2019-07-24 Dana-Farber Cancer Institute, Inc. CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
JP7493304B2 (ja) 2016-04-22 2024-05-31 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｅｚｈ２インヒビターおよびそれらの使用
US20230330140A1 (en) * 2019-11-25 2023-10-19 Ansun Biopharma, Inc. Immune cell delivery of sialidase cancer cells, immune cells and the tumor microenvironment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081624A1 (en) * 2002-09-06 2004-04-29 Chrysalis Technologies Incorporated Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols
US20090142327A1 (en) * 2002-11-22 2009-06-04 Fang Fang Novel Class of Therapeutic Protein Based Molecules
US20110171132A1 (en) * 2009-11-06 2011-07-14 Nexbio, Inc. Methods, Compounds, and Compositions for Treatment and Prophylaxis in the Respiratory Tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
CA2506526C (en) 2002-11-22 2017-04-18 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
CN101404980A (zh) * 2006-01-24 2009-04-08 耐百生物制药有限公司 大分子微球的制备技术

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081624A1 (en) * 2002-09-06 2004-04-29 Chrysalis Technologies Incorporated Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols
US20090142327A1 (en) * 2002-11-22 2009-06-04 Fang Fang Novel Class of Therapeutic Protein Based Molecules
US20110171132A1 (en) * 2009-11-06 2011-07-14 Nexbio, Inc. Methods, Compounds, and Compositions for Treatment and Prophylaxis in the Respiratory Tract
CN102711807A (zh) * 2009-11-06 2012-10-03 耐百生物制药有限公司 用于在呼吸道中进行治疗和预防的方法、化合物和组合物

Also Published As

Publication number Publication date
IL234116B (en) 2020-03-31
US20170151315A1 (en) 2017-06-01
EP2841092A4 (en) 2015-09-16
IL273194B2 (en) 2023-02-01
US20130280332A1 (en) 2013-10-24
ES2970401T3 (es) 2024-05-28
CN109529026A (zh) 2019-03-29
EP2841092B1 (en) 2023-12-06
US20210046165A1 (en) 2021-02-18
JP2015508780A (ja) 2015-03-23
AU2013221230A1 (en) 2014-10-02
IL273194B (en) 2022-10-01
HK1207975A1 (en) 2016-02-19
AU2019226190B2 (en) 2021-10-07
CA2864746A1 (en) 2013-08-22
AU2017258955A1 (en) 2017-12-14
AU2019226190A1 (en) 2019-09-26
US20150132274A1 (en) 2015-05-14
EP2841092C0 (en) 2023-12-06
WO2013123521A1 (en) 2013-08-22
EP2841092A1 (en) 2015-03-04
IL273194A (en) 2020-04-30
US20250387457A1 (en) 2025-12-25

Similar Documents

Publication Publication Date Title
US20250387457A1 (en) Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients
US8709496B2 (en) Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract
WO2011057081A1 (en) Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract
CN115427576B (zh) 包括透明质酸和蛋白聚糖连接蛋白1的用于预防或治疗肺部疾病的组合物
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
EP4232073B1 (en) New dosage regimen for inhaled vasoactive intestinal polypeptide
CN112546046B (zh) 盐酸阿比朵尔在制备治疗肺纤维化疾病药物中的应用
EP4248986A1 (en) Use of polypeptide having superoxide dismutase activity and extracellular vesicles for treatment or prevention of respiratory viral infection
EP2544705B1 (en) Interferon beta for use in the treatment of lower respiratory tract illness caused by influenza
AU2019389806B2 (en) Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
US12440488B2 (en) Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension
HK40004532A (en) Methods, compounds and compositions for treating influenza and parainfluenza patients
Arruda et al. Update on therapy of influenza and rhinovirus infections
CN108926707A (zh) Pf4的抗rsv应用
HK1207975B (en) Compounds and compositions for use in a method of treatment of parainfluenza virus
WO2024096742A1 (en) SARS-CoV-2 BINDING POLYPEPTIDE
EP4612174A1 (en) Sars-cov-2 binding antibody
WO2023198757A1 (en) Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
CN115461356A (zh) 用于预防或治疗covid-19的肽

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141210